{"article_link": "https://www.frontiersin.org/articles/10.3389/fcell.2021.649265/full", "data": [{"id": "data_1", "omics": "Transcriptomics", "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE163574", "format": "txt", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE163574"}, {"id": "data_2", "omics": "Proteomics", "link": "https://www.ebi.ac.uk/pride/archive/projects/PXD023344", "format": "raw", "source": "ProteomeXchange", "public_id": "PXD023344"}, {"id": "data_3", "omics": "Phosphoproteomics", "link": "https://www.ebi.ac.uk/pride/archive/projects/PXD023345", "format": "raw", "source": "ProteomeXchange", "public_id": "PXD023345"}, {"id": "data_4", "omics": "Transcriptomics", "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62452", "format": "txt", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE62452"}, {"id": "data_5", "omics": "Transcriptomics", "link": "https://icgc.org", "format": "txt", "source": "International Cancer Genome Consortium (ICGC)", "public_id": "ICGC_AU"}, {"id": "data_6", "omics": "Transcriptomics", "link": "https://portal.gdc.cancer.gov/", "format": "txt", "source": "The Cancer Genome Atlas (TCGA)", "public_id": "TCGA_PAAD"}], "analyses": [{"id": "analysis_1", "analysis_name": "Raw Data Processing", "analysis_data": ["data_1"], "label": {"Treatment": ["anlotinib-treated", "DMSO control"]}}, {"id": "analysis_2", "analysis_name": "Differential analysis", "analysis_data": ["data_1"], "label": {"Criteria": ["Fold change >= 2", "FDR < 0.05"]}}, {"id": "analysis_3", "analysis_name": "Pathway analysis", "analysis_data": ["analysis_2"], "label": {"Method": ["IPA"]}}, {"id": "analysis_4", "analysis_name": "Proteomics", "analysis_data": ["data_2"], "label": {"Differential expression criteria": ["Fold change > 1.2", "p-value < 0.05"]}}, {"id": "analysis_5", "analysis_name": "Phosphoproteomics", "analysis_data": ["data_3"], "label": {"Differential expression criteria": ["Fold change > 1.2", "p-value < 0.05"]}}, {"id": "analysis_6", "analysis_name": "Integrated multi-omics analysis", "analysis_data": ["analysis_2", "analysis_4", "analysis_5"], "label": {"Integration method": ["Transcriptomics", "Proteomics", "Phosphoproteomics"]}}, {"id": "analysis_7", "analysis_name": "Classification analysis", "analysis_data": ["analysis_6"], "label": {"Cut-off value": "0.5", "Cohorts": ["GSE62452", "ICGC_AU"]}}, {"id": "analysis_8", "analysis_name": "Regression analysis", "analysis_data": ["analysis_7"], "label": null}, {"id": "analysis_9", "analysis_name": "Pathway enrichment and biomarker identification", "analysis_data": ["analysis_6"], "label": {"Method": ["GSEA"]}}, {"id": "analysis_10", "analysis_name": "Post-transcriptional regulation analysis", "analysis_data": ["analysis_2", "analysis_4"], "label": {"Mechanism": ["Ribosome biogenesis", "Lysosomal function"]}}], "results": [{"analysis_id": "analysis_1", "metrics": "IC50", "value": "5.535 (PANC-1); 4.642 (AsPC-1)", "features": null}, {"analysis_id": "analysis_2", "metrics": "Number of DEGs", "value": "992", "features": null}, {"analysis_id": "analysis_3", "metrics": "Enriched pathways", "value": "24 cancer-related canonical pathways", "features": ["Unfolded protein response", "Cell cycle: G2/M DNA damage checkpoint regulation", "p53 signaling pathway", "Role of BRCA1 in DNA damage response"]}, {"analysis_id": "analysis_4", "metrics": "Number of differentially expressed proteins", "value": "1046", "features": ["Ribosome", "Lysosome"]}, {"analysis_id": "analysis_5", "metrics": "Number of differentially phosphorylated peptides", "value": "4323", "features": ["Cell cycle", "RNA transport", "Spliceosome"]}, {"analysis_id": "analysis_6", "metrics": "Shared mechanisms", "value": "Post-transcriptional regulation of ribosome and lysosome", "features": ["Ribosome biogenesis", "Lysosomal function"]}, {"analysis_id": "analysis_7", "metrics": "Stratification rate", "value": "57% of patients categorized into high-risk group", "features": null}, {"analysis_id": "analysis_8", "metrics": "Hazard Ratio (HR)", "value": "2.318 (risk score); 1.831 (N stage)", "features": ["risk score", "N stage"]}, {"analysis_id": "analysis_9", "metrics": "AUC", "value": "0.7 (3 years), 0.72 (5 years) in TCGA_PAAD; 0.87 (3 years), 0.85 (5 years) in GSE62452; 0.65 (3 years), 0.75 (5 years) in ICGC_AU", "features": ["TOP2A", "CRABP2", "CDK1", "NUSAP1", "PERP"]}]}